Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor

Non-alcoholic fatty liver disease (NAFLD) is increasing globally, and seeking therapeutic molecule targets is urgent. Several studies have demonstrated that IL-33 plays an important role in the progression of Non-alcoholic steatohepatitis (NASH) with fibrosis and the proliferation of hepatocellular...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes and its complications 2024-01, Vol.38 (1), p.108650-108650, Article 108650
Hauptverfasser:	Wakamatsu, Sho, Jojima, Teruo, Hashiguchi, Masaaki, Kishi, Haruka, Niitani, Takafumi, Sakurai, Shintaro, Iijima, Toshie, Kogai, Takahiko, Tomaru, Takuya, Usui, Isao, Aso, Yoshimasa
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer's disease Animals Antibodies Carcinoma, Hepatocellular - prevention & control Cell cycle Cell growth Collagen Cytokines Diabetes Diabetes Mellitus - drug therapy Disease Models, Animal Glucose Interleukin-33 - metabolism Interleukin-33 - therapeutic use Liver - metabolism Liver cancer Liver Cirrhosis - drug therapy Liver Cirrhosis - etiology Liver Cirrhosis - prevention & control Liver diseases Liver Neoplasms - prevention & control Mice Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - metabolism Proteins Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Sorbitol - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!